Synopsis
Motivation:
Goals:
Approach:
Results:
361-02-002
ISMRM Abstract
MRI-based habitat analysis for discriminating prostate cancer from benign prostatic hyperplasia: a dual-center study
Accepted
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.
To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.
Log inReferences
1. Lee S W H, Chan E M C, and Lai Y K The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep 2017. 7(1): 7984.doi: 10.1038/s41598-017-06628-8. [doi]
2. Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022. CA Cancer J Clin 2022. 72(1): 7-33.doi: 10.3322/caac.21708. [doi]
3. Thompson I M, Ankerst D P, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006. 98(8): 529-34.doi: 10.1093/jnci/djj131. [doi]
4. Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 2012. 30(9): 1323-41.doi: 10.1016/j.mri.2012.05.001. [doi]
5. De Visschere P J, Vral A, Perletti G, et al. Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate. Eur Radiol 2017. 27(5): 2095-2109.doi: 10.1007/s00330-016-4479-z. [doi]
6. Sun Z, Wang K, Wu C, et al. Using an artificial intelligence model to detect and localize visible clinically significant prostate cancer in prostate magnetic resonance imaging: a multicenter external validation study. Quant Imaging Med Surg 2024. 14(1): 43-60.doi: 10.21037/qims-23-791. [doi]
7. Bi Q, Miao K, Xu N, et al. Habitat Radiomics Based on MRI for Predicting Platinum Resistance in Patients with High-Grade Serous Ovarian Carcinoma: A Multicenter Study. Acad Radiol 2024. 31(6): 2367-2380.doi: 10.1016/j.acra.2023.11.038. [doi]
8. Shi Z, Huang X, Cheng Z, et al. MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology 2023. 308(1): e222830.doi: 10.1148/radiol.222830. [doi]
9. Zhang Y, Yang C, Qian X, et al. Evaluate the Microvascular Invasion of Hepatocellular Carcinoma (≤5 cm) and Recurrence Free Survival with Gadoxetate Disodium-Enhanced MRI-Based Habitat Imaging. J Magn Reson Imaging 2024. 60(4): 1664-1675.doi: 10.1002/jmri.29207. [doi]
10. Cai Z, Xu Z, Chen Y, et al. Multiparametric MRI subregion radiomics for preoperative assessment of high-risk subregions in microsatellite instability of rectal cancer patients: a multicenter study. Int J Surg 2024. 110(7): 4310-4319.doi: 10.1097/js9.0000000000001335. [doi]
11. Franco O E, Jiang M, Strand D W, et al. Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 2011. 71(4): 1272-81.doi: 10.1158/0008-5472.Can-10-3142. [doi]
12. Steinbach C, Merchant A, Zaharie A T, et al. Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies. Cancers (Basel) 2022. 14(22): 10.3390/cancers14225719. [doi]
13. Gui S, Lan M, Wang C, et al. Application Value of Radiomic Nomogram in the Differential Diagnosis of Prostate Cancer and Hyperplasia. Front Oncol 2022. 12(859625.doi: 10.3389/fonc.2022.859625. [doi]
14. Hu L, Zhou D W, Fu C X, et al. Advanced zoomed diffusion-weighted imaging vs. full-field-of-view diffusion-weighted imaging in prostate cancer detection: a radiomic features study. Eur Radiol 2021. 31(3): 1760-1769.doi: 10.1007/s00330-020-07227-4. [doi]
Cite this abstract
http://echo.ismrm.org/p/ISMRM2026/361-02-002